Author: Jeremy M. Levin
Publisher: Rosetta Books
ISBN: 0795352980
Category : Business & Economics
Languages : en
Pages : 263
Book Description
47 leaders from across the biotechnology industry tell their stories of battling the global scourge of COVID-19. Pandemics have killed at least a half billion people over the past two millennia. But in the age of biotechnology, humanity is no longer defenseless. The biotechnology industry is a diverse community of scientists, doctors, patients, entrepreneurs, investors, bankers, analysts and reporters, all committed to treating and curing disease. Over the past forty years, it has produced medical advances at an electrifying rate. As the COVID-19 pandemic emerged, hundreds of companies quickly pivoted to combating the virus. The contributors to this book offer inside views of this seminal industry, with historical and personal perspectives, lessons learned, and looks into the future. Diverse as these leaders are, they are united by their conviction that science and medicine will light humanity’s way to greater health and longevity.
Biotechnology in the Time of COVID-19
Made in China
Author: Jasper Becker
Publisher: Oxford University Press
ISBN: 1787386120
Category : Political Science
Languages : en
Pages : 344
Book Description
What might COVID-19 mean for, and reveal about, China's place in the world? The coronavirus pandemic started in Wuhan, home to the leading lab studying the SARS virus and bats. Was that pure coincidence? This book explores what we know, and still don't know, about the origins of COVID-19, and how it was handled in China. We may never get all the answers, but much is already clear: China's record as the origin of earlier pandemics, and its struggle to bring contagious diseases under control; its history as both a victim of biological warfare and a developer of deadly bioweapons. When Covid broke out, Wuhan was building science parks to realise Beijing's ambitions in biotech research. Whoever achieves global leadership of the gene-editing industry stands to harvest great power and wealth. China has already challenged Western technological supremacy with 5G and in other industries. Yet this tiny, invisible virus has cruelly exposed a critical flaw in the Chinese political system: obsessive secrecy. The West wanted to trust the PRC, hoping that, as it prospered, it would become an open society. Made in China reveals how Beijing's leaders have betrayed that trust.
Publisher: Oxford University Press
ISBN: 1787386120
Category : Political Science
Languages : en
Pages : 344
Book Description
What might COVID-19 mean for, and reveal about, China's place in the world? The coronavirus pandemic started in Wuhan, home to the leading lab studying the SARS virus and bats. Was that pure coincidence? This book explores what we know, and still don't know, about the origins of COVID-19, and how it was handled in China. We may never get all the answers, but much is already clear: China's record as the origin of earlier pandemics, and its struggle to bring contagious diseases under control; its history as both a victim of biological warfare and a developer of deadly bioweapons. When Covid broke out, Wuhan was building science parks to realise Beijing's ambitions in biotech research. Whoever achieves global leadership of the gene-editing industry stands to harvest great power and wealth. China has already challenged Western technological supremacy with 5G and in other industries. Yet this tiny, invisible virus has cruelly exposed a critical flaw in the Chinese political system: obsessive secrecy. The West wanted to trust the PRC, hoping that, as it prospered, it would become an open society. Made in China reveals how Beijing's leaders have betrayed that trust.
From Breakthrough to Blockbuster
Author: Donald L. Drakeman
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Publisher: Oxford University Press
ISBN: 0195084004
Category : Biotechnology industries
Languages : en
Pages : 241
Book Description
"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--
Disability, Health, Law, and Bioethics
Author: I. Glenn Cohen
Publisher: Cambridge University Press
ISBN: 1108485979
Category : Health & Fitness
Languages : en
Pages : 313
Book Description
Examines how the framing of disability has serious implications for legal, medical, and policy treatments of disability.
Publisher: Cambridge University Press
ISBN: 1108485979
Category : Health & Fitness
Languages : en
Pages : 313
Book Description
Examines how the framing of disability has serious implications for legal, medical, and policy treatments of disability.
Biomedical Innovations to Combat COVID-19
Author: Sergio Rosales-Mendoza
Publisher: Academic Press
ISBN: 0323902499
Category : Medical
Languages : en
Pages : 411
Book Description
Biomedical Innovations to Combat COVID-19 provides an updated overview on the development of vaccines, antiviral drugs and nanomaterials, and diagnostic methods for the fight against COVID-19. Perspectives on such technologies are identified, discussed, and enriched with figures for easy understanding and applicability. Furthermore, it contains basic aspects of virology, immunology, and antiviral drugs that are needed to fully appreciate these innovations. This book is split into four sections: introduction, presenting basic virologic and epidemiological aspects of COVID-19; vaccines against COVID-19, discussing their different types and applications used to develop them; diagnostic approaches for SARS-CoV-2, encompassing advanced sensing and microfluidic-based biosensors; and drug development and delivery, where antivirals based on nanomaterials or drugs are presented. It is a valuable source for virologists, biotechnologists, and members of biomedical field interested in learning more about how novel technologies can be applied to fasten the eradication of the COVID-19 and similar pandemics. - Presents updated literature coverage summarizing the most relevant information on COVID-19 - Written by experts from diverse scientific domains in order to provide readers with a thorough view on the subject - Encompasses tables, figures and information trees especially developed for the book in order to condense and highlight key points for quick reference
Publisher: Academic Press
ISBN: 0323902499
Category : Medical
Languages : en
Pages : 411
Book Description
Biomedical Innovations to Combat COVID-19 provides an updated overview on the development of vaccines, antiviral drugs and nanomaterials, and diagnostic methods for the fight against COVID-19. Perspectives on such technologies are identified, discussed, and enriched with figures for easy understanding and applicability. Furthermore, it contains basic aspects of virology, immunology, and antiviral drugs that are needed to fully appreciate these innovations. This book is split into four sections: introduction, presenting basic virologic and epidemiological aspects of COVID-19; vaccines against COVID-19, discussing their different types and applications used to develop them; diagnostic approaches for SARS-CoV-2, encompassing advanced sensing and microfluidic-based biosensors; and drug development and delivery, where antivirals based on nanomaterials or drugs are presented. It is a valuable source for virologists, biotechnologists, and members of biomedical field interested in learning more about how novel technologies can be applied to fasten the eradication of the COVID-19 and similar pandemics. - Presents updated literature coverage summarizing the most relevant information on COVID-19 - Written by experts from diverse scientific domains in order to provide readers with a thorough view on the subject - Encompasses tables, figures and information trees especially developed for the book in order to condense and highlight key points for quick reference
The Vaccine
Author: Joe Miller
Publisher: St. Martin's Press
ISBN: 1250280370
Category : Biography & Autobiography
Languages : en
Pages : 272
Book Description
Winners of the Paul Ehrlich Prize The dramatic story of the married scientists who founded BioNTech and developed the first vaccine against COVID-19. Nobody thought it was possible. In mid-January 2020, Ugur Sahin told Özlem Türeci, his wife and decades-long research partner, that a vaccine against what would soon be known as COVID-19 could be developed and safely injected into the arms of millions before the end of the year. His confidence was built upon almost thirty years of research. While working to revolutionize the way that cancerous tumors are treated, the couple had explored a volatile and overlooked molecule called messenger RNA; they believed it could be harnessed to redirect the immune system's forces against any number of diseases. As the founders of BioNTech, they faced widespread skepticism from the scientific community at first; but by the time Sars-Cov-2 was discovered in Wuhan, China, BioNTech was prepared to deploy cutting edge technology and create the world’s first clinically approved inoculation for the coronavirus. The Vaccine draws back the curtain on one of the most important medical breakthroughs of our age; it will reveal how Doctors Sahin and Türeci were able to develop twenty vaccine candidates within weeks, convince Big Pharma to support their ambitious project, navigate political interference from the Trump administration and the European Union, and provide more than three billion doses of the Pfizer/BioNTech vaccine to countries around the world in record time. Written by Joe Miller—the Financial Times’ Frankfurt correspondent who covered BioNTech’s COVID-19 project in real time—with contributions from Sahin and Türeci, as well as interviews with more than sixty scientists, politicians, public health officials, and BioNTech staff, the book covers key events throughout the extraordinary year, as well as exploring the scientific, economic, and personal background of each medical innovation. Crafted to be both completely accessible to the average reader and filled with details that will fascinate seasoned microbiologists, The Vaccine explains the science behind the breakthrough, at a time when public confidence in vaccine safety and efficacy is crucial to bringing an end to this pandemic.
Publisher: St. Martin's Press
ISBN: 1250280370
Category : Biography & Autobiography
Languages : en
Pages : 272
Book Description
Winners of the Paul Ehrlich Prize The dramatic story of the married scientists who founded BioNTech and developed the first vaccine against COVID-19. Nobody thought it was possible. In mid-January 2020, Ugur Sahin told Özlem Türeci, his wife and decades-long research partner, that a vaccine against what would soon be known as COVID-19 could be developed and safely injected into the arms of millions before the end of the year. His confidence was built upon almost thirty years of research. While working to revolutionize the way that cancerous tumors are treated, the couple had explored a volatile and overlooked molecule called messenger RNA; they believed it could be harnessed to redirect the immune system's forces against any number of diseases. As the founders of BioNTech, they faced widespread skepticism from the scientific community at first; but by the time Sars-Cov-2 was discovered in Wuhan, China, BioNTech was prepared to deploy cutting edge technology and create the world’s first clinically approved inoculation for the coronavirus. The Vaccine draws back the curtain on one of the most important medical breakthroughs of our age; it will reveal how Doctors Sahin and Türeci were able to develop twenty vaccine candidates within weeks, convince Big Pharma to support their ambitious project, navigate political interference from the Trump administration and the European Union, and provide more than three billion doses of the Pfizer/BioNTech vaccine to countries around the world in record time. Written by Joe Miller—the Financial Times’ Frankfurt correspondent who covered BioNTech’s COVID-19 project in real time—with contributions from Sahin and Türeci, as well as interviews with more than sixty scientists, politicians, public health officials, and BioNTech staff, the book covers key events throughout the extraordinary year, as well as exploring the scientific, economic, and personal background of each medical innovation. Crafted to be both completely accessible to the average reader and filled with details that will fascinate seasoned microbiologists, The Vaccine explains the science behind the breakthrough, at a time when public confidence in vaccine safety and efficacy is crucial to bringing an end to this pandemic.
SARS-CoV-2 Spike Protein Convergent Evolution
Author: Daniele Focosi
Publisher: Springer Nature
ISBN: 3030873242
Category : Medical
Languages : en
Pages : 140
Book Description
This book reviews the current knowledge of the globally circulating SARS-CoV-2 variants, highlights their distinct genetic characteristics and associated conformational changes in the viral spike protein, and profoundly discusses the mechanisms of convergent evolution that led to the rise of these mutated strains at different geographic regions during the Covid-19 pandemic. Furthermore, the book explores how these variants do and may impact the efficacy of established neutralizing antibody-based (nAb) vaccines and therapeutics by analysing latest in vivo and in vitro clinical data. Finally, the author discusses ways on how nAb Covid-19 treatment derived immune escape of SARS-CoV-2 could be minimized in the future.
Publisher: Springer Nature
ISBN: 3030873242
Category : Medical
Languages : en
Pages : 140
Book Description
This book reviews the current knowledge of the globally circulating SARS-CoV-2 variants, highlights their distinct genetic characteristics and associated conformational changes in the viral spike protein, and profoundly discusses the mechanisms of convergent evolution that led to the rise of these mutated strains at different geographic regions during the Covid-19 pandemic. Furthermore, the book explores how these variants do and may impact the efficacy of established neutralizing antibody-based (nAb) vaccines and therapeutics by analysing latest in vivo and in vitro clinical data. Finally, the author discusses ways on how nAb Covid-19 treatment derived immune escape of SARS-CoV-2 could be minimized in the future.
Evidence-Based Practice for Public Health Emergency Preparedness and Response
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309670381
Category : Medical
Languages : en
Pages : 501
Book Description
When communities face complex public health emergencies, state local, tribal, and territorial public health agencies must make difficult decisions regarding how to effectively respond. The public health emergency preparedness and response (PHEPR) system, with its multifaceted mission to prevent, protect against, quickly respond to, and recover from public health emergencies, is inherently complex and encompasses policies, organizations, and programs. Since the events of September 11, 2001, the United States has invested billions of dollars and immeasurable amounts of human capital to develop and enhance public health emergency preparedness and infrastructure to respond to a wide range of public health threats, including infectious diseases, natural disasters, and chemical, biological, radiological, and nuclear events. Despite the investments in research and the growing body of empirical literature on a range of preparedness and response capabilities and functions, there has been no national-level, comprehensive review and grading of evidence for public health emergency preparedness and response practices comparable to those utilized in medicine and other public health fields. Evidence-Based Practice for Public Health Emergency Preparedness and Response reviews the state of the evidence on PHEPR practices and the improvements necessary to move the field forward and to strengthen the PHEPR system. This publication evaluates PHEPR evidence to understand the balance of benefits and harms of PHEPR practices, with a focus on four main areas of PHEPR: engagement with and training of community-based partners to improve the outcomes of at-risk populations after public health emergencies; activation of a public health emergency operations center; communication of public health alerts and guidance to technical audiences during a public health emergency; and implementation of quarantine to reduce the spread of contagious illness.
Publisher: National Academies Press
ISBN: 0309670381
Category : Medical
Languages : en
Pages : 501
Book Description
When communities face complex public health emergencies, state local, tribal, and territorial public health agencies must make difficult decisions regarding how to effectively respond. The public health emergency preparedness and response (PHEPR) system, with its multifaceted mission to prevent, protect against, quickly respond to, and recover from public health emergencies, is inherently complex and encompasses policies, organizations, and programs. Since the events of September 11, 2001, the United States has invested billions of dollars and immeasurable amounts of human capital to develop and enhance public health emergency preparedness and infrastructure to respond to a wide range of public health threats, including infectious diseases, natural disasters, and chemical, biological, radiological, and nuclear events. Despite the investments in research and the growing body of empirical literature on a range of preparedness and response capabilities and functions, there has been no national-level, comprehensive review and grading of evidence for public health emergency preparedness and response practices comparable to those utilized in medicine and other public health fields. Evidence-Based Practice for Public Health Emergency Preparedness and Response reviews the state of the evidence on PHEPR practices and the improvements necessary to move the field forward and to strengthen the PHEPR system. This publication evaluates PHEPR evidence to understand the balance of benefits and harms of PHEPR practices, with a focus on four main areas of PHEPR: engagement with and training of community-based partners to improve the outcomes of at-risk populations after public health emergencies; activation of a public health emergency operations center; communication of public health alerts and guidance to technical audiences during a public health emergency; and implementation of quarantine to reduce the spread of contagious illness.
A Prescription for Change
Author: Michael Kinch
Publisher: UNC Press Books
ISBN: 146963063X
Category : Medical
Languages : en
Pages : 355
Book Description
The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes--and indeed because of them--our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy. To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.
Publisher: UNC Press Books
ISBN: 146963063X
Category : Medical
Languages : en
Pages : 355
Book Description
The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes--and indeed because of them--our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy. To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.
Coronavirus Disease 2019 (COVID-19)
Author: Shailendra K. Saxena
Publisher:
ISBN: 9789811548154
Category : Coronavirus infections
Languages : en
Pages :
Book Description
This book provides a comprehensive overview of recent novel coronavirus (SARS-CoV-2) infection, their biology and associated challenges for their treatment and prevention of novel Coronavirus Disease 2019 (COVID-19). Discussing various aspects of COVID-19 infection, including global epidemiology, genome organization, immunopathogenesis, transmission cycle, diagnosis, treatment, prevention, and control strategies, it highlights host-pathogen interactions, host immune response, and pathogen immune invasion strategies toward developing an immune intervention or preventive vaccine for COVID-19. An understanding of the topics covered in the book is imperative in the context of designing strategies to protect the human race from further losses and harm due to SARS-CoV-2 infection causing COVID-19.
Publisher:
ISBN: 9789811548154
Category : Coronavirus infections
Languages : en
Pages :
Book Description
This book provides a comprehensive overview of recent novel coronavirus (SARS-CoV-2) infection, their biology and associated challenges for their treatment and prevention of novel Coronavirus Disease 2019 (COVID-19). Discussing various aspects of COVID-19 infection, including global epidemiology, genome organization, immunopathogenesis, transmission cycle, diagnosis, treatment, prevention, and control strategies, it highlights host-pathogen interactions, host immune response, and pathogen immune invasion strategies toward developing an immune intervention or preventive vaccine for COVID-19. An understanding of the topics covered in the book is imperative in the context of designing strategies to protect the human race from further losses and harm due to SARS-CoV-2 infection causing COVID-19.